It’s estimated that approximately 1 in 9 Australians have asthma, and based on international estimates, of those people living with asthma around 3%-10% may have severe asthma.1-3

 

Asthma is recognised by the Global Initiative for Asthma (GINA) Guidelines as a heterogenous disease, usually characterised by chronic airway inflammation.4 Severe asthma is defined as:

 

IMAGE

 

Uncontrolled, persistent asthma is characterised by chronic inflammation and airway hyperresponsiveness (AHR). This may lead to airway remodeling and reduced lung function in the small and large airways.

Type 2 inflammation

Type 2 inflammation is an read more

Testing & Diagnosis

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat..

IL-4 and IL-13 Signalling

IL-4 and IL-13 Signalling

Screening & Testing

Screening & Testing

Treatment Options

Treatment Options

References

  1. 1.AIHW 2017 Snapshot: https://www.aihw.gov.au/reports/asthma-other-chronic-respiratory-conditions/asthma/data
  2. 2.Hekking et al. J Allergy Clin Immunol 2015; 135(4): 896–902.
  3. 3.Chung et al. Eur Respir J 2014; 43(2): 343–73.
  4. 4.Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2020. Available from: www.ginasthma.org (accessed November 2020).
  1. 5.Tran TN et al. Ann Allergy Asthma Immunol 2016; 116(1): 37–42.
  2. 6.Seys SF et al. Respir Res 2017; 18(1): 39.
  3. 7.Peters MC et al. J Allergy Clin Immunol 2014; 133(2): 388–94.